Riskpilot← Back to searchSign inGet full accessEvolan Medic AB
ABActiveOrg 5568874258Svärdvägen 19Manufacture of pharmaceutical preparations · NACE 2120Est. 20120 employees
Revenue 2025
SEK 14,7M
+19% vs 2024
EBITDA margin
45.9%
+22% vs 2024
Equity ratio
81.0%
Financial strength
Net profit 2025
SEK 5,4M
+23% vs 2024
| Revenue | SEK 14,7M | +19% |
| EBITDA | SEK 6,7M | +22% |
| Net profit | SEK 5,4M | +23% |
| Total assets | SEK 6,7M | +6% |
| Equity | SEK 5,4M | +23% |
| Employees | 0 | — |
Legal name
Evolan Medic AB
Org number
5568874258
Legal form
Aktiebolag
NACE code
2120 · Manufacture of pharmaceutical preparations
Founded
13 mars 2012
Share capital
SEK 50 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2025-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas var för sig av Jern, Lars Eric Karroum, Said Richard
Company purpose
Bolaget ska bedriva försäljning och produktion av läkemedel samt därmed förenlig verksamhet.
Address
Svärdvägen 19
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | 5 656 | 5 527 | 4 261 | 5 748 | 6 876 | 5 648 | 12 293 | 14 676 |
| Staff expenses | — | — | — | — | — | — | — | — | — | — | — |
| EBITDA | 2 459 | 2 625 | 2 956 | 2 400 | 2 648 | 1 972 | 2 760 | 3 130 | 2 316 | 5 508 | 6 734 |
| Depreciation & amort. | −172 | −172 | −165 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | — |
| EBIT | 2 287 | 2 453 | 2 791 | 2 400 | 2 648 | 1 972 | 2 760 | 3 130 | 2 316 | 5 508 | 6 734 |
| Net financials | 11 | 6 | −2 | — | — | 4 | — | 7 | 10 | −60 | 18 |
| Profit before tax | 2 540 | 2 459 | 2 789 | 2 400 | 2 648 | 1 976 | 2 761 | 3 137 | 2 326 | 5 493 | 6 752 |
| Tax | −559 | −541 | −614 | −528 | −567 | −423 | −569 | −646 | −479 | −1 131 | −1 390 |
| Net profit | 1 981 | 1 918 | 2 175 | 1 872 | 2 081 | 1 553 | 2 192 | 2 491 | 1 847 | 4 362 | 5 362 |
| Item | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 2 656 | 2 179 | 3 248 | 2 826 | 2 207 | 1 785 | 2 393 | 2 722 | 2 176 | 6 278 | 6 685 |
| Equity | 2 151 | 1 969 | 2 243 | 1 925 | 2 207 | 1 660 | 2 251 | 2 542 | 1 899 | 4 412 | 5 412 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | — |
| Short-term debt | 505 | 210 | 1 005 | 901 | 0 | 125 | 142 | 180 | 277 | 1 866 | 1 273 |
| Total debt | 505 | 210 | 1 005 | 901 | — | 125 | 142 | 180 | 277 | 1 866 | 1 273 |
EBITDA margin
45.9%
This company
15.8%
Market median
+191% vs market
20152025
Equity ratio
81.0%
This company
38.2%
Market median
+112% vs market
20152025
Return on equity
99.1%
This company
18.4%
Market median
+439% vs market
20152025
Net profit margin
36.5%
This company
8.1%
Market median
+351% vs market
20152025
Asset turnover
2.20×
This company
1.12×
Market median
+96% vs market
20152025
Debt / equity
0.24×
This company
0.62×
Market median
+61% vs market
20152025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2025-01-01 – 2025-12-31
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Bolagsverket / SCB · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via Bolagsverket / SCB · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via Bolagsverket / SCB · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via Bolagsverket / SCB · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via Bolagsverket / SCB · Period 2015-01-01 – 2015-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
RN Chief Auditor | Chief Auditor | 2022 | — | — |
SR Chief Executive Officer | Chief Executive Officer | 2022 | — | — |
PM Chief Auditor | Chief Auditor | 2025 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2022 | — | — | |
| Board of Directors | 2024 | — | — | |
| Board of Directors | 2022 | — | — | |
| Chairman | 2022 | — | — |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Evolan Medic AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Rolf Nicklas Kullberg | Chief Auditor | 0 companies |
| Said Richard Karroum | Chief Executive Officer | 0 companies |
| Peter Magnus Kangas | Chief Auditor | 0 companies |
| Anders Leif Håkansson | Board of Directors | 0 companies |
| Sven Fredrik Syrén Engström | Board of Directors | 0 companies |
| Nils Patrik Johansson | Board of Directors | 0 companies |
| Lars Eric Jern | Chairman | 0 companies |